Ageing with HIV

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2018 Feb 15

PMID 29443936

Citations 20

Authors

Padraig McGettrick

Elena Alvarez Barco

Patrick W G Mallon

Affiliations

Soon will be listed here.

Abstract

The population of people living with HIV (PLWH) is growing older with an estimated 4 million over the age of 50 years, a figure which has doubled since the introduction of effective antiretroviral therapy (ART) and which is increasing globally. Despite effective ART, PLWH still experience excess morbidity and mortality compared to the general population with increased prevalence of age-related, non-AIDS illnesses (NAI) such as cardiovascular disease, malignancies, cognitive impairment and reduced bone mineral density, which impact disability and everyday functioning. This review will discuss the challenges presented by comorbidities in ageing PLWH and discuss the aetiology and management of age-related illnesses in this vulnerable population.

Citing Articles

Understanding stigma as a barrier to cancer prevention and treatment: a qualitative study among people living with HIV in Uganda and Zambia.

Guy K, Arinaitwe J, Goma F, Atuyambe L, Guwatudde D, Zyambo C BMJ Open. 2025; 15(3):e090817.

PMID: 40074264 PMC: 11904343. DOI: 10.1136/bmjopen-2024-090817.

Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts.

Tiendrebeogo T, Malateste K, Poda A, Minga A, Lahiri C, Ezechi O J Int AIDS Soc. 2024; 27(12):e26371.

PMID: 39604062 PMC: 11602402. DOI: 10.1002/jia2.26371.

Association Between TyG Index, Liver Steatosis and Immunosenescence in People Living with HIV.

Yan H, Chen S, Gao X, Jiang Y, Liang G, Peng J Infect Drug Resist. 2024; 17:5049-5059.

PMID: 39559341 PMC: 11570526. DOI: 10.2147/IDR.S493140.

Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.

Kumar P, Clarke A, Jonsson-Oldenbuttel C, Garcia Deltoro M, Di Giambenedetto S, Brites C AIDS Behav. 2024; 29(1):235-245.

PMID: 39225890 PMC: 11739274. DOI: 10.1007/s10461-024-04479-9.

B cells and atherosclerosis: A HIV perspective.

Obare L, Bonami R, Doran A, Wanjalla C J Cell Physiol. 2024; 239(6):e31270.

PMID: 38651687 PMC: 11209796. DOI: 10.1002/jcp.31270.

References

John M, Greene M, Hessol N, Zepf R, Parrott A, Foreman C . Geriatric Assessments and Association With VACS Index Among HIV-Infected Older Adults in San Francisco. J Acquir Immune Defic Syndr. 2016; 72(5):534-41. PMC: 4942400. DOI: 10.1097/QAI.0000000000001009. View

Worm S, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F . Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009; 201(3):318-30. DOI: 10.1086/649897. View

Negredo E, Diez-Perez A, Bonjoch A, Domingo P, Perez-Alvarez N, Gutierrez M . Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J Antimicrob Chemother. 2015; 70(7):2104-7. DOI: 10.1093/jac/dkv063. View

Molsberry S, Lecci F, Kingsley L, Junker B, Reynolds S, Goodkin K . Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study. AIDS. 2015; 29(6):713-21. PMC: 4743499. DOI: 10.1097/QAD.0000000000000561. View

Grant I, Franklin Jr D, Deutsch R, Woods S, Vaida F, Ellis R . Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014; 82(23):2055-62. PMC: 4118496. DOI: 10.1212/WNL.0000000000000492. View

Engels E, Pfeiffer R, Goedert J, Virgo P, McNeel T, Scoppa S . Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006; 20(12):1645-54. DOI: 10.1097/01.aids.0000238411.75324.59. View

Piketty C, Selinger-Leneman H, Bouvier A, Belot A, Mary-Krause M, Duvivier C . Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol. 2012; 30(35):4360-6. DOI: 10.1200/JCO.2012.44.5486. View

Joska J, Westgarth-Taylor J, Myer L, Hoare J, Thomas K, Combrinck M . Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav. 2010; 15(6):1197-203. DOI: 10.1007/s10461-010-9744-6. View

Dillon S, Kibbie J, Lee E, Guo K, Santiago M, Austin G . Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS. 2016; 31(4):511-521. PMC: 5263163. DOI: 10.1097/QAD.0000000000001366. View

10.

Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J . Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3):M146-56. DOI: 10.1093/gerona/56.3.m146. View

11.

Arnsten J, Freeman R, Howard A, Floris-Moore M, Lo Y, Klein R . Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007; 21(5):617-23. PMC: 2426821. DOI: 10.1097/QAD.0b013e3280148c05. View

12.

Feinstein M, Bahiru E, Achenbach C, Longenecker C, Hsue P, So-Armah K . Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. Am J Cardiol. 2015; 117(2):214-20. PMC: 5308060. DOI: 10.1016/j.amjcard.2015.10.030. View

13.

Deeks S, Lewin S, Havlir D . The end of AIDS: HIV infection as a chronic disease. Lancet. 2013; 382(9903):1525-33. PMC: 4058441. DOI: 10.1016/S0140-6736(13)61809-7. View

14.

Freiberg M, Chang C, Kuller L, Skanderson M, Lowy E, Kraemer K . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8):614-22. PMC: 4766798. DOI: 10.1001/jamainternmed.2013.3728. View

15.

Cotter A, Mallon P . Therapeutic options for low bone mineral density in HIV-infected subjects. Curr HIV/AIDS Rep. 2012; 9(2):148-59. DOI: 10.1007/s11904-012-0117-9. View

16.

Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A . Osteopenia in HIV-infected patients: is it the disease or is it the treatment?. AIDS. 2001; 15(6):807-8. DOI: 10.1097/00002030-200104130-00022. View

17.

Handley S, Desai C, Zhao G, Droit L, Monaco C, Schroeder A . SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. Cell Host Microbe. 2016; 19(3):323-35. PMC: 4802495. DOI: 10.1016/j.chom.2016.02.010. View

18.

Brothers T, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston B . Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014; 210(8):1170-9. DOI: 10.1093/infdis/jiu258. View

19.

Zanni M, Fitch K, Feldpausch M, Han A, Lee H, Lu M . 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014; 28(14):2061-70. PMC: 4405159. DOI: 10.1097/QAD.0000000000000360. View

20.

Ancuta P, Kamat A, Kunstman K, Kim E, Autissier P, Wurcel A . Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008; 3(6):e2516. PMC: 2424175. DOI: 10.1371/journal.pone.0002516. View